At NeoShyne, reliability is more than a value — it’s our foundation.
From cultivation to compliance, every process is designed for precision, transparency, and full traceability. We deliver hemp-derived ingredients that meet the world’s most stringent quality and documentation standards — trusted by partners across the United States, Japan, the European Union, and other regulated markets.
NeoShyne combines U.S. cultivation excellence, scientific rigor from Asia, and international compliance discipline.
Across more than 500 acres of controlled hemp farms operating under Good Agricultural and Collection Practices (GACP), we produce raw materials with non-detectable THC (ND-THC ≤ 0.0001 % / 1 ppm) verified by accredited laboratories.
Every production cycle is monitored, validated, and recorded, ensuring stable output, full traceability, and dependable supply for long-term partners around the world.
Each batch is accompanied by a comprehensive compliance dossier, prepared according to international and regional regulations:
All documents are available in bilingual or region-specific formats for seamless review and importer submission.
All materials are produced under controlled environments for uniformity, stability, and global compliance.
NeoShyne operates within the legal frameworks of each region where hemp and CBD products are regulated and permitted:
Through strict THC control, verified documentation, and executive-level accountability, NeoShyne ensures every product meets both international benchmarks and local regulatory expectations.
We don’t just export CBD — we deliver confidence, consistency, and compliance engineered for every market we serve.
NeoShyne, powered by NeoCannbio and built on the research expertise of KIST (Korea Institute of Science and Technology), is leading the development of cannabinoid-based medical drugs as cost-effective alternatives to imported medicines such as Epidiolex and Sativex.
The Center focuses on producing API-grade cannabinoids like CBD and expanding its cannabinoid library to discover new therapeutic applications.
Combining biotech expertise with global business insight, he drives NeoShyne’s innovation-focused growth through science-based strategy and leadership.
Through innovative cultivation and extraction expertise, he leads global growth in hydroponics and hemp-based wellness.
Driving innovation across cannabis and sustainable products, he builds strong consumer brands and market expansion.
Through finding effective cannabinoids and producing related materials, NeoCannBio is focused on developing medical products which can fight rare diseases together with NeoShyne.
Korea's medical cannabis industry, which started from the Gyeongbuk Hemp Regulation Free Zone, will reach the global market through KIST-technology-based NeoCannBio.
